INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Multiple Presentations at the 2018 Society for Immunotherapy of Cancer Conference
Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- NantKwest (NASDAQ: NK), a leading,
View HTML
Toggle Summary NantKwest to Present at 2018 Cantor Global Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2 nd in New York City
View HTML
Toggle Summary NantKwest Names Sonja Nelson Chief Financial Officer
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 19, 2018-- NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson , chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This press release features multimedia.
View HTML
Toggle Summary NantKwest to Present at Jefferies 2018 Global Healthcare Conference
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong , Chairman & CEO of NantKwest , will be presenting and conducting one-on-one meetings at the upcoming
View HTML
Toggle Summary NantKwest to Present at Upcoming Science & Medicine Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 23, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018 .
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment and Healthcare Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
View HTML
Toggle Summary NantKwest to Present at Upcoming Investment and Healthcare Conferences
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
View HTML
Toggle Summary Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Feb. 13, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, today announced that
View HTML
Toggle Summary Dr. Patrick Soon-Shiong Presents at the 36th Annual J.P. Morgan Healthcare Conference
Download Presentation (PDF) To watch the Webcast To Listen to the Webcast
View HTML
Toggle Summary Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks , the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.
View HTML